Daxor (DXR)
Supplies blood-volume diagnostic kits and BVA analyzers.
Something off on this page? Send us feedback.
Radiopharmaceutical and medical-device manufacturer selling Volumex diagnostic kits for use with its BVA Companion Analyzer. It develops and manufactures BVA systems in Oak Ridge while seeking to exit its legacy closed-end investment-company registration.
Blood-volume analysis is provided through Volumex diagnostic kits used with the BVA Companion Analyzer. The radiopharmaceutical and medical-device manufacturer develops, tests, builds, and commercializes BVA systems at its Oak Ridge, Tennessee facility after an earlier cryobanking business.
Rights for Volumex and Megatope, plus exclusive Glofil rights, were acquired with the stated aim of internalizing manufacturing. The business depends on the Oak Ridge facility for BVA manufacture, testing, commercial production, and next-generation development. A pending SEC application seeks to end the legacy closed-end investment-company registration; no final deregistration order was identified.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Feb 11, 2026 | Lake Street | Target | $23 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.8M · Total debt $0 · Total assets $51.9M · Shareholders' equity $51.8M
- Revenue
- $23.0K
- Operating income
- −$3.3M
- Net income
- −$3.3M
No dividends on record.
| Institutions14 holders · as of Mar 31, 2026 | 7.20% | 420.1K shares | |
| Insiders4 holders · as of Sep 1, 2026 | 6.54% | 381.7K shares | |
| Otherremainder | 86.26% | 5.04M shares |
5.84M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Michael Richard FeldschuhInsiderdirector, officer: Chief Executive Officer | 4.17% | 243,694 | Form 4filed Jun 25, 2026 ↗ |
Thompson Siegel & Walmsley LLCInstitution | 3.98% | 232,120 | 13Fas of Mar 31, 2026 |
Jonathan Adam FeldschuhInsiderdirector, officer: Chief Scientific Officer | 1.35% | 78,908 | Form 4filed Jun 25, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 0.83% | 48,280 | 13Fas of Mar 31, 2026 |
Aristides Capital LLCInstitution | 0.71% | 41,692 | 13Fas of Mar 31, 2026 |
| See all 24 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 8, 2026 | Michael Richard Feldschuh | director, officer: Chief Executive Officer | +1,000 | $9.07 |
| Mar 31, 2026 | Robert J. Michel | officer: Chief Financial Officer | +1,000 | $9.90 |
| Mar 20, 2026 | John Jefferies | officer: Chief Medical Officer | +5,941 | |
| Dec 9, 2025 | Jonathan Adam Feldschuh | director, officer: Chief Scientific Officer | +18,000 | |
| Dec 9, 2025 | Robert J. Michel | officer: Chief Financial Officer | +3,000 |
- BD
Advanced hemodynamic monitoring in acute and critical care
- Baxter International
Noninvasive fluid-responsiveness monitoring for unstable patients
- Danaher
Advanced hemodynamic monitoring for operating rooms and high-acuity care
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Daxor | $10.10 | −7.34% | $62.7M | 8.6 | — | 404.9 | — |
| BD | $189.24 | +0.88% | $51.67B | 56.5 | 14.2 | 2.5 | −9.6% |
| Baxter International | $25.61 | −0.31% | $13.29B | — | 12.2 | 1.2 | +5.3% |
| Danaher | $209.00 | −0.43% | $147.59B | 37.3 | 23.6 | 5.9 | +5.5% |
| Median | 46.9 | 14.2 | 2.5 | +5.3% |